-
Mashup Score: 0Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability - 1 year(s) ago
A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Zahra Mahmoudjafari, PharmD, BCOP, discussed the post hoc analysis from the REACH2 trial and highlighted the key takeaways.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In REACH2, a randomized, open-label phase 3 study, 302 patients were included in the safety analysis. Among those enrolled, 152 were randomized to receive 10 mg of oral #ruxolitinib twice a day while 150 were assigned to 1 of 9 BAT options. #GVHD https://t.co/fZTPuIXJMi
-
-
Mashup Score: 0Abbas Assesses the Use of Allogenic Transplant In MPNs - 1 year(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jonathan Abbas, MD, discussed the use of allogeneic hematopoietic stem cell transplant in patients with MPNs and how #ruxolitinib fits into their care. #mpnsm https://t.co/MmCV0oXs8A
-
-
Mashup Score: 0
The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has issued a complete response letter for #ruxolitinib extended-release tablets for once-daily use for the treatment of certain types of #myelofibrosis, polycythemia vera, and #GVHD. #mpnsm | @AaronGerds @ClevelandClinic https://t.co/m7YHjP86sY
-
-
Mashup Score: 0Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo - 1 year(s) ago
Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Tune in to this @AJMC_Journal interview as Dr John Harris (@HarrisVitiligo) discusses the treatment of #Ruxolitinib cream for #vitiligo, which he presented at the 2023 @AADskin conference. #AAD Watch now! https://t.co/9amN8TGiBc https://t.co/5DVw1erpJ6
-
-
Mashup Score: 0Approved Therapies for Myelofibrosis - 1 year(s) ago
A comprehensive overview of ruxolitinib, fedratinib, and pacritinib, the approved therapies for the treatment of myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Aaron Gerds, MD, provides an overview of #ruxolitinib, #fedratinib, and #pacritinib for the treatment of #myelofibrosis. #mpnsm | @ClevelandClinic @AaronGerds https://t.co/NIWpWMi5v0
-
-
Mashup Score: 1Navitoclax Added to Ruxolitinib Improves Spleen Volume and Symptoms in Myelofibrosis - 1 year(s) ago
The ability to modify disease in patients with myelofibrosis was signaled in the REFINE study. The combination also displayed positive efficacy and was tolerable.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combining #navitoclax and #ruxolitinib may improve splenomegaly & symptoms or modify disease in patients with #myelofibrosis, the #REFINE study shows. #mpnsm https://t.co/ID6brxEt47
-
-
Mashup Score: 2
Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The introduction of #ruxolitinib improved overall survival in patients with #aGVHD and decreased the rate of non-relapse mortality. Visit our websitefor more conference coverage from #Tandem23 https://t.co/lo4hejhTG5
-
-
Mashup Score: 2
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, talked about #ruxolitinib and the role it may play in improving long-term outcomes for patients with #myelofibrosis. #mpnsm | @MoffittNews https://t.co/ikif1q7YO1
-
-
Mashup Score: 0The Role of Ruxolitinib in Myelofibrosis Treatment - 1 year(s) ago
Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Srdan Verstovsek, MD, discusses how #ruxolitinib might fit into the #myelofibrosis treatment landscape in the future, and highlights remaining unmet needs. #mpnsm | @MDAndersonNews https://t.co/c3TofT8VHs
-
A pair of posters presented at the @AADskin 2023 Annual Meeting showed the efficacy of #ruxolitinib cream in improving symptoms of #vitiligo on the face. Learn more! https://t.co/WBHwDqheoS https://t.co/O69YKc6DIw